Z Squared Inc. annual report, FY2024

Business Context and Reporting Period

Company: Coeptis Therapeutics Holdings, Inc. (COEP)

Filing Type: Form 10-K (Annual Report)

Reporting Period: Fiscal Year Ended December 31, 2024

Business Overview: Coeptis is a biopharmaceutical and technology holding company. Its primary focus is the development of cell therapy platforms for cancer, autoimmune, and infectious diseases, specifically through its GEAR-NK and SNAP-CAR technologies. The company also operates a technology segment focused on AI-powered marketing software (NexGenAI). The company is classified as an Emerging Growth Company and a Smaller Reporting Company.

Key Financial Metrics

Metric 2024 2023
Revenue $0 $0
Net Loss $(10,877,412) $(21,266,537)
Operating Expenses $10,054,488 $21,491,125
Cash and Cash Equivalents (End of Period) $532,885 $1,469,134
Total Assets $8,908,660 $4,571,089
Total Liabilities $5,041,434 $3,757,125
Accumulated Deficit $(98,233,673) $(87,356,260)
Shares Outstanding (Common) 2,116,191 (post 20-1 split) 1,766,552 (post 20-1 split)

Note: All share and per-share data has been retrospectively adjusted for a 20-for-1 reverse stock split effective December 31, 2024.

Material Changes vs. Prior Period

  • Operating Expenses: Decreased significantly by approximately 53% from $21.5 million in 2023 to $10.1 million in 2024. This reduction was primarily driven by lower research and development expenses in 2024 compared to the significant one-time costs associated with the Deverra Therapeutics transaction in 2023.
  • Net Loss: Improved from $21.3 million in 2023 to $10.9 million in 2024, reflecting the decrease in operating expenses.
  • Liquidity: Cash balances decreased by approximately 64% from $1.47 million to $0.53 million. The company utilized cash for operations and financing activities.
  • Capital Structure: The company completed a Series A Preferred Stock offering, raising approximately $10 million (with $2.1 million recorded as subscription receivable at year-end). Additionally, the company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, resulting in a new convertible note and a derivative liability.
  • Derivative Liabilities: A new derivative liability of $1.04 million was recorded in 2024 related to the SEPA, compared to none in 2023. Warrant liabilities decreased from $0.56 million to $0.36 million.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

Management does not expect to generate significant revenue for at least the next year. The company anticipates continuing to incur operating losses and negative cash flow from operations. Future profitability is dependent on the successful development and commercialization of product candidates or strategic partnerships.

Recent Developments

  • SEPA: Entered into a Standby Equity Purchase Agreement with Yorkville allowing the sale of up to $20 million of common stock. A convertible note of $1.3 million was issued as a pre-paid advance.
  • Series A Offering: Completed a $10 million Series A Preferred Stock offering (closed in February 2025).
  • GEAR License: In March 2025, the company secured exclusive worldwide rights to the GEAR Cell Therapy Platform from Vy-Gen-Bio, Inc., committing to a $400,000 license fee.

Risks and Contingencies

  • Going Concern: The independent auditor has issued a report indicating substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and working capital deficits. The financial statements do not include adjustments that might result from this uncertainty.
  • Financing Needs: The company requires additional financing to fund operations and development. Failure to secure capital could force the company to delay or terminate development programs.
  • Regulatory Approval: All product candidates are in pre-clinical or early clinical stages. There is no assurance that clinical trials will be successful or that regulatory approval will be obtained.
  • Nasdaq Compliance: The company previously faced delisting risks due to minimum bid price requirements but regained compliance in January 2025.

Unusual Items

  • Debt Extinguishment: Recorded a $200,000 loss on the extinguishment of debt related to the Yorkville SEPA transaction.
  • Derivative Fair Value: Recognized a $539,660 loss on the change in fair value of the derivative liability associated with the SEPA.

Investor Verification Checklist

  • Cash Runway: Verify the sufficiency of the $532,885 cash balance against current burn rates and the timeline for the Series A Preferred Stock closing (completed Feb 2025).
  • Going Concern Status: Review the auditor's "Substantial Doubt" paragraph and management's specific plans to raise capital to sustain operations.
  • Derivative Liability Impact: Assess the volatility of the $1.04 million derivative liability tied to the SEPA and its potential impact on future earnings.
  • Series A Terms: Examine the conversion terms, liquidation preferences, and voting rights of the Series A Preferred Stock issued to investors.
  • GEAR Platform Rights: Confirm the financial obligations and milestones associated with the new exclusive license agreement with Vy-Gen-Bio, Inc.
  • Reverse Stock Split: Ensure all historical share data is adjusted for the 20-for-1 reverse stock split effective December 31, 2024.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.